Recro Pharma (REPH) Reports Q2 Loss of $0.83/Share

Recro Pharma (NASDAQ: REPH) reported Q2 EPS of ($0.83), versus ($0.17) reported last year. Revenue for the quarter came in at $17.3 million, versus $18.7 million reported last year.

For earnings history and earnings-related data on Recro Pharma (REPH) click here.

You May Also Be Interested In

• Iridium Communications (IRDM) Reports In-Line Q1 EPS; offers outlook
• Nokia slightly down as Q1 profit growth fails to meet consensus; outlook unchanged
• Home Bancshares (HOMB) Tops Q1 EPS by 3c